Clinical Trial Update: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Cretostimogene in non-muscle-invasive bladder cancer unresponsive to BCG, currently recruiting by Lepu Biopharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer High-grade Ta T1 Papillary
• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Cretostimogene (cretostimogene)

Snippet

Sponsor: Lepu Biopharma Co., Ltd. | Conditions: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | Phase 2 | Status: RECRUITING